Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongbo Lu

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2015
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic LeukemiaNaval Daver, Yanis Boumber, Hagop Kantarjian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2014
Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemiaMarina Y Konopleva, Roland B Walter, Stefan H Faderl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2015
Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia ModelsJuliana Benito, Marc S Ramirez, Niki Zacharias Millward, et al.
Haematologica|February 16, 2015
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemiaMarina Konopleva, Peter F Thall, Cecilia Arana Yi, et al.
Cell Chemical Biology|March 2, 2023
Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapySimone Bonazzi, Eva d'Hennezel, Rohan E J Beckwith, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2015
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic LeukemiaNaval Daver, Yanis Boumber, Hagop Kantarjian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2014
Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemiaMarina Y Konopleva, Roland B Walter, Stefan H Faderl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2015
Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia ModelsJuliana Benito, Marc S Ramirez, Niki Zacharias Millward, et al.
Haematologica|February 16, 2015
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemiaMarina Konopleva, Peter F Thall, Cecilia Arana Yi, et al.
Cell Chemical Biology|March 2, 2023
Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapySimone Bonazzi, Eva d'Hennezel, Rohan E J Beckwith, et al.
Pageof 9